VIATRIS™

Q3 2025 Financial Results

Total Revenues	Adjusted EBITDA*	Adjusted EPS*	Free Cash Flow* Excluding Transaction-related Costs
$3.8B	**$1.2B**	**$0.67**	**$728M**

"We delivered another strong quarter by staying focused on our 2025 strategic priorities. Our performance this quarter reflects the continued strength of our execution across markets. We are advancing our pipeline with key regulatory submissions and preparing for multiple potential launches, while preparing to take meaningful actions through our enterprise-wide strategic review to position Viatris for sustainable growth in 2026 and beyond. We remain confident in our strategy, our people, and our ability to deliver significant impact for patients and long-term value for shareholders."

– Scott A. Smith
Chief Executive Officer

Delivering on Our 2025 Strategic Priorities

- Drive strong commercial execution
- Advance our pipeline
- Prioritize capital return with focus on share repurchases
- Target accretive regional business development
- Complete remediation for Indore facility and request reinspection
- Conduct enterprise-wide strategic review

Execution

- Q3 operational performance in line with expectations, with 1% total revenue growth ex Indore [(1)]
- Submitted NDA for our low dose estrogen weekly patch
- Returned >$920M of capital to shareholders YTD [(2)], including $500M share repurchases and ~$420M dividends paid
- Acquired Aculys Pharma, receiving exclusive rights to pitolisant in Japan and Spydia® in Japan and certain other markets in the Asia-Pacific region
- Indore facility initial remediation activities substantially complete and recently met with U.S. FDA to discuss our progress and potential timing for reinspection
- Significant progress on our enterprise-wide strategic review

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our Third Quarter 2025 Financial Results press release on our website.

(1) Divestiture-adjusted operational change ex Indore based on Q3 2025 total revenues as compared to Q3 2024 total revenues adj ex divestitures further adjusted for the negative impact related to Indore of ~$100M vs the comparable 2024 period.

(2) Year-to-date capital return through November 5, 2025.

Viatris.com | LinkedIn | @ViatrisInc | @ViatrisInc | YouTube | Listen Well Podcast